NasdaqCM - Nasdaq Real Time Price • USD
Pulse Biosciences, Inc. (PLSE)
As of 12:46 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Robert W. Duggan | Executive Chairman | -- | -- | 1945 |
Mr. Darrin R. Uecker | CTO & Director | 834.73k | -- | 1966 |
Mr. Mitchell E. Levinson | Chief Strategy Officer | 584.57k | -- | 1960 |
Dr. Richard Nuccitelli Ph.D. | Chief Science Officer | -- | -- | -- |
Mr. Kenneth B. Stratton Esq., J.D. | General Counsel & Corporate Secretary | -- | -- | 1969 |
Ms. Patty Perla | Vice President of Human Resources | -- | -- | -- |
Mr. David Danitz | Senior Vice President of Engineering | -- | -- | -- |
Dr. Gansevoort Dunnington M.D. | Chief Medical Officer | -- | -- | -- |
Dr. Niv Ad M.D. | Chief Science Officer of Cardiac Surgery | -- | -- | -- |
Pulse Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Medical Instruments & Supplies
Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Corporate Governance
Pulse Biosciences, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 6; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 23, 2024DEFA14A: Proxy StatementsSee Full Filing
- Apr 15, 2024S-3/A: Offering RegistrationsSee Full Filing
- Mar 28, 202410-K: Periodic Financial ReportsSee Full Filing
- Mar 11, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 14, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 07, 2024
Pulse Biosciences, Inc. Earnings Call
Related Tickers
KRMD KORU Medical Systems, Inc.
2.1800
-0.46%
SRT3.DE Sartorius Aktiengesellschaft
290.20
+2.87%
MLSS Milestone Scientific Inc.
0.5796
+1.68%
MMSI Merit Medical Systems, Inc.
74.01
+0.86%
NYXH Nyxoah S.A.
9.80
-8.92%
LMAT LeMaitre Vascular, Inc.
65.15
+3.43%
ICUI ICU Medical, Inc.
95.58
+1.11%
BLFS BioLife Solutions, Inc.
17.03
+1.01%
OSUR OraSure Technologies, Inc.
5.34
+1.43%
ANGO AngioDynamics, Inc.
5.82
+0.69%